Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?

Bresalier, Robert; Kopetz, Scott; Brenner, Dean
March 2015
Digestive Diseases & Sciences;Mar2015, Vol. 60 Issue 3, p664
Academic Journal
Colorectal cancer is the second leading cause of cancer death in industrialized nations, accounting for 10 % of the total cancer burden with an individual lifetime risk of ~6 % in the USA (Siegel et al. in CA Cancer J Clin 62:9-29, , American Cancer Society in Colorectal cancer facts and figures 2011-2013. American Cancer Society, Atlanta, , Siegel et al. in CA Cancer J Clin 61:212-236, ). Although numerous screening methods have been incorporated into guidelines for colorectal cancer screening, no guideline includes a noninvasive blood-based test as a recommended option.


Related Articles

  • Detection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT). Heigh, Russell I.; Yab, Tracy C.; Taylor, William R.; Hussain, Fareeda T. N.; Smyrk, Thomas C.; Mahoney, Douglas W.; Domanico, Michael J.; Berger, Barry M.; Lidgard, Graham P.; Ahlquist, David A. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Objectives: Precursors to 1/3 of colorectal cancer (CRC), serrated polyps have been under-detected by screening due to their inconspicuous, non-hemorrhagic, and proximal nature. A new multi-target stool DNA test (multi-target sDNA) shows high sensitivity for both CRC and advanced adenomas....

  • Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening. Ahlquist, David // Digestive Diseases & Sciences;Mar2015, Vol. 60 Issue 3, p623 

    Stool DNA testing has evolved into what is now a highly accurate and well-validated test for the screen detection of colorectal neoplasia. An optimized and automated multi-target stool DNA test (MT-sDNA) has achieved the same high point-sensitivities as reported for colonoscopy and significantly...

  • Enzo Biochem Launch of Test for Measuring Risk of Colorectal Cancer Underscores Growing Role of Molecular Diagnostics.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that Enzo Biochem Inc. has launched the ColonSentry test for assessing a patient's risk of having colorectal cancer. ColonSentry is a first of its kind blood-based risk stratification test for colorectal cancer. The test utilizes RNA to measure the level of expression of...

  • Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer. Toon, Christopher W.; Chou, Angela; Clarkson, Adele; DeSilva, Keshani; Houang, Michelle; Chan, Joseph C. Y.; Sioson, Loretta L.; Jankova, Lucy; Gill, Anthony J. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    MYC over-expression as determined by molecular means has been reported as a favorable prognostic biomarker in colorectal carcinoma (CRC). However MYC expression analysis is not available in the routine clinical setting. We investigated whether immunohistochemistry (IHC) for the myc protein using...

  • PD-0023 VALIDATION STUDY OF A BLOOD-BASED GENE EXPRESSION SIGNATURE FOR COLORECTAL CANCER DETECTION. Xu, Q.; Ye, X.; Wu, F.; Meng, X. // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii13 

    No abstract available.

  • What an abnormal FIT result really means. Telford, Jennifer J. // British Columbia Medical Journal;Mar2014, Vol. 56 Issue 2, p97 

    The article discusses British Columbia's Colon Screening Program that was introduced in November 2013 and offers colorectal cancer screening to asymptomatic patients aging 50-74 through the fecal immunochemical test.

  • A New Generation of Molecular Stool Testing. Mak, Tony; Hill, James // Current Medical Literature: Colorectal Cancer;2011, Vol. 4 Issue 4, p105 

    The article discusses the pathophysiology of colorectal neoplasia and describes the existing modalities in molecular stool testing for colorectal cancer (CRC) screening. It says that molecular stool testing can become a significant alternative method to fecal occult blood testing (FBOT). It...

  • Medical oncology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS58 

    Presents an abstract of the research manuscript `Poor prognosis associated with elevated serum CA19-9 level in metastatic colorectal adenocarcinoma,' by A. Wong and A. Chan. Serum tumor marker CA19-9.

  • Identification of a Circulating MicroRNA Signature for Colorectal Cancer Detection. Wang, Jia; Huang, Sheng-kai; Zhao, Mei; Yang, Mei; Zhong, Jia-ling; Gu, Yu-yu; Peng, Hua; Che, Yi-qun; Huang, Chang-zhi // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Prognosis of patients with colorectal cancer (CRC) is generally poor because of the lack of simple, convenient, and noninvasive tools for CRC detection at the early stage. The discovery of microRNAs (miRNAs) and their different expression profiles among different kinds of diseases has opened a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics